Citius Oncology(Ctor) Financials: Cash Ratio Compared To Industry Average, Plus Other Key Ratios
Liquidity Trend (Last 5 Years)
Liquidity - cash ratio
This chart shows the historical trend of cash ratio for CTOR compared to its industry average over the recent years.
Ratio Definition and Interpretation
Name: Cash Ratio
Definition: The cash ratio measures a company's ability to pay off all of its current liabilities immediately using only its most liquid assets: cash and cash equivalents. Unlike the current ratio and quick ratio, it excludes accounts receivable and inventory, making it the most conservative measure of liquidity.
Interpretation:
• In '2022', CTOR's cash ratio was 0.00, indicating the company's ability to meet short-term obligations purely with cash. Industry average for Biotechnology: Pharmaceutical Preparations in '2022' stood at 2.56.
• In '2023', CTOR's cash ratio was 0.00, indicating the company's ability to meet short-term obligations purely with cash. The figure remained stable compared to '2022'. Industry average for Biotechnology: Pharmaceutical Preparations in '2023' stood at 2.27. Industry average declined by 0.29 from previous year.
• In '2024', CTOR's cash ratio was 0.00, indicating the company's ability to meet short-term obligations purely with cash. The figure remained stable compared to '2023'. Industry average for Biotechnology: Pharmaceutical Preparations in '2024' stood at 2.14. Industry average declined by 0.13 from previous year.
Overall, CTOR's cash ratio has remained generally stable over the past 3 years.
Formula: Cash Ratio = (Cash + Cash Equivalents) / Current Liabilities
Good Range: Generally, a cash ratio between 0.2 and 0.5 is considered healthy for most industries.